THE PROS AND CONS OF MODERN ANTICOAGULANT THERAPY
DOI:
https://doi.org/10.56782/pps.119Keywords:
antithrombotic drugs, bleeding, therapy managementAbstract
Antithrombotic drugs are the mainstay of treatment and prevention of thromboembolic disease. The principal risk of antithrombotic therapy is a severe bleeding that requires an appropriate medical intervention. The overall strategy of managing a major bleeding in patients receiving anticoagulants includes the cessation of therapy, as well as an attempt to reverse any remaining antithrombotic effects using, if available, specific antidotes or general procoagulants. In the present review, we discuss the most commonly used anticoagulants, including their mechanisms of action, pharmacokinetics, and side effects, as well as general guidelines for management of major bleeding in patients treated with these drugs. In addition, we describe approaches, currently at the preclinical and clinical study stage, with the potential to improve the safety of anticoagulant therapy in the future. We present an example of the contribution of pharmacists to an increased efficacy and safety of anticoagulant treatments.
Downloads
References
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR, American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012, 141, e419S-e494S. DOI: https://doi.org/10.1378/chest.11-2301
You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY, American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141, e531S-e575S. DOI: https://doi.org/10.1378/chest.11-2304
Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr, American College of Cardiology, American Heart Association, Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). J. Am. Coll. Cardiol., 2002, 40, 1366-1374.
Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126, 287S-310S. DOI: https://doi.org/10.1378/chest.126.3_suppl.287S
Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch. Intern. Med., 2000, 160, 181-188. DOI: https://doi.org/10.1001/archinte.160.2.181
Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann. Intern. Med., 1999, 130, 800-809. DOI: https://doi.org/10.7326/0003-4819-130-10-199905180-00003
Costantino G, Ceriani E, Rusconi AM, Podda GM, Montano N, Duca P, Cattaneo M, Casazza G. Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review. PLoS ONE, 2012, 7, e44553. DOI: https://doi.org/10.1371/journal.pone.0044553
Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA, 2004, 292, 89-96. DOI: https://doi.org/10.1001/jama.292.1.89
Blazing MA1, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, 'A to Z' Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA, 2004, 292, 55-64. DOI: https://doi.org/10.1001/jama.292.1.55
Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA, 2004, 292, 45-54. DOI: https://doi.org/10.1001/jama.292.1.45
Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, Manthous CA. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest, 2004, 125, 856-863. DOI: https://doi.org/10.1378/chest.125.3.856
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA, 2006, 295, 1519-1530. DOI: https://doi.org/10.1001/jama.295.13.joc60038
Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med., 2003, 349, 1695-1702. DOI: https://doi.org/10.1056/NEJMoa035451
Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med., 2004, 140, 867-873.
Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, American College of Cardiology, American Heart Association Task Force on Practice Guidelines, Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J. Am. Coll. Cardiol., 2004, 44, e1-e211.
Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126, 401S-428S. DOI: https://doi.org/10.1378/chest.126.3_suppl.401S
Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126, 338S-400S. DOI: https://doi.org/10.1378/chest.126.3_suppl.338S
Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb. Haemost., 2008, 99, 807-818. DOI: https://doi.org/10.1160/TH08-01-0032
Hirsh J, Bauer KA, Donati MB, Gould, M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008, 133, 141S-159S. DOI: https://doi.org/10.1378/chest.08-0689
Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012, 141, e24S-e43S. DOI: https://doi.org/10.1378/chest.11-2291
Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A. The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol, 2016, 12, 897-909. DOI: https://doi.org/10.1080/17425255.2016.1194395
Sokołowska E, Mogielnicki A. Poszukiwanie następców protaminy: skuteczne i bezpieczne hamowanie krwawienia wywołanego podaniem pozajelitowych środków przeciwkrzepliwych. Biul. Wydz. Farm. WUM, 2016, 2, 7-16. DOI: https://doi.org/10.56782/pps.102
Shenoi RA, Kalathottukaren MT, Travers RJ, Lai BFL, Creag AL, Lange D, Yu K, Weinhart M, Chew BH, Du C, Brooks DE, Carter CJ, Morrissey JH, Haynes CA, Kizhakkedathu JN. Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Sci. Transl. Med., 2014, 6, 260ra150. DOI: https://doi.org/10.1126/scitranslmed.3009427
Kalaska B, Sokolowska E, Kaminski K, Szczubialka K, Mogielnicki A, Nowakowska M, Buczko W. Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis. Eur. J. Pharmacol., 2012, 686, 81-89. DOI: https://doi.org/10.1016/j.ejphar.2012.04.037
Kaminski K, Kalaska B, Koczurkiewicz P, Michalik M, Szczubialka K, Mogielnicki A, Buczko W, Nowakowska M. New arginine substituted derivative of poly(allylamine hydrochloride) for heparin reversal. Med. Chem. Commun., 2014, 5, 489-495. DOI: https://doi.org/10.1039/c3md00374d
Kalaska B, Kaminski K, Sokolowska E, Czaplicki D, Kujdowicz M, Stalińska K, Bereta J, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A. Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin. PLoS ONE, 2015, 10, e0119486. DOI: https://doi.org/10.1371/journal.pone.0119486
Sokolowska E, Kalaska B, Kaminski K, Lewandowska A, Błażejczyk A, Wietrzyk J, Kasacka I, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A. The toxicokinetic profile of Dex40-GTMAC3 - a novel polysaccharide candidate for reversal of unfractionated heparin. Front. Pharmacol., 2016, 7, 60. DOI: https://doi.org/10.3389/fphar.2016.00060
Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med., 2013, 19, 446-451. DOI: https://doi.org/10.1038/nm.3102
Ansell J, Bakhru SH, Laulicht SS, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. N. Engl. J. Med. 2014, 371, 2141-2142. DOI: https://doi.org/10.1056/NEJMc1411800
Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb. Haemost., 1990, 63, 271-274. DOI: https://doi.org/10.1055/s-0038-1645207
Holst J, Lindblad B, Bergqvist D, Garre K, Nielsen H, Hedner U, Ostergaard PB. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers. Blood Coagul. Fibrinolysis, 1994, 5, 795-803. DOI: https://doi.org/10.1097/00001721-199410000-00018
Van Veen JJ, Maclean RM, Hampton KK, Laidlaw S, Kitchen S, Toth P, Makris M. Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul. Fibrinolysis, 2011, 22, 565-570. DOI: https://doi.org/10.1097/MBC.0b013e3283494b3c
Ingerslev J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J. Postgrad. Med., 2007, 53, 17-22. DOI: https://doi.org/10.4103/0022-3859.30322
Lauritzen B, Hedner U, Johansen PB, Tranholm M, Ezban M. Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats. J. Thromb. Haemost., 2008, 6, 804-811. DOI: https://doi.org/10.1111/j.1538-7836.2008.02933.x
Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br. J. Haematol., 2013, 160, 35-46. DOI: https://doi.org/10.1111/bjh.12107
Kalaska B, Kaminski K, Miklosz J, Shin-ichi Y, Sokolowska E, Blazejczyk A, Wietrzyk J, Kasacka I, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A. Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin and fondaparinux in rats and mice. Transl. Res., 2016, 177, 98-112. DOI: https://doi.org/10.1016/j.trsl.2016.06.009
Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb. Res., 2003, 109, 1-11. DOI: https://doi.org/10.1016/S0049-3848(03)00030-6
Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, de Greef R. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet., 2012, 41, 1-9. DOI: https://doi.org/10.2165/00003088-200241002-00001
Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med., 2002, 162, 1833-1840. DOI: https://doi.org/10.1001/archinte.162.16.1833
Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb. Haemost., 2008, 100, 350-355. DOI: https://doi.org/10.1160/TH07-05-0357
Desmurs-Clavel H, Huchon C, Chatard B, Negrier C, Dargaud Y. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb. Res., 2009, 123, 796-798. DOI: https://doi.org/10.1016/j.thromres.2008.07.007
Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Büller HR, Levi M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation, 2002, 106, 2550-2554. DOI: https://doi.org/10.1161/01.CIR.0000038501.87442.02
Luporsi P, Chopard R, Janin S, Racadot E, Bernard Y, Ecarnot F, Séronde MF, Briand F, Guignier A, Descotes-Genon V, Meneveau N, Schiele F. Use of recombinant factor VIIa (NovoSeven) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Card. Care, 2011, 13, 93-98. DOI: https://doi.org/10.3109/17482941.2011.567281
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2009, 361, 1139-1151 DOI: https://doi.org/10.1056/NEJMoa0905561
Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 2011, 365, 883-891. DOI: https://doi.org/10.1056/NEJMoa1009638
Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch. Intern. Med., 2000, 16011, 1612-1617. DOI: https://doi.org/10.1001/archinte.160.11.1612
Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N. Engl. J. Med., 1995, 3331, 11-17. DOI: https://doi.org/10.1056/NEJM199507063330103
Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, Blostein MD, Kahn SR, Vesely SK, Schulman S, Kovacs MJ, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann. Intern. Med., 2009, 1505, 293-300.
Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O’malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch. Intern. Med., 2006, 1664, 391-397. DOI: https://doi.org/10.1001/.391
Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH, American College of Chest Physicians. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest, 2012, 141, e152S-e184S DOI: https://doi.org/10.1378/chest.11-2295
Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch. Intern. Med., 2003, 16320, 2469-2473. DOI: https://doi.org/10.1001/archinte.163.20.2469
Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost., 2010, 103, 1116-1127. DOI: https://doi.org/10.1160/TH09-11-0758
Syed YY. Idarucizumab: A Review as a Reversal Agent for Dabigatran. Am. J. Cardiovasc. Drugs., 2016, 16, 297-304. DOI: https://doi.org/10.1007/s40256-016-0181-4
Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, Ezekowitz MD. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J., 2013, 34, 1498-1505. DOI: https://doi.org/10.1093/eurheartj/eht039
Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med., 2016, 375, 534-544. DOI: https://doi.org/10.1056/NEJMoa1601747
Olesen JB, Christiansen K, Ingerslev J, Sorensen B, Hvas A. Haemostatic response to in vitro addition of recombinant factor Vila, prothrombin complex concentrate, or concentrate of Factor IX/X in blood spiked with a direct Xa inhibitor. J Thromb Haemost, 2009, 7, PP-Mo-386.
Perzborn E, Harwardt M. Recombinant factor VIIa partially reverses the effects of the factor anti Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. J. Thromb. Haemost., 2007, 5, W640.
Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology, 2012, 116, 94-102. DOI: https://doi.org/10.1097/ALN.0b013e318238c036
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 2011, 124, 1573-1579. DOI: https://doi.org/10.1161/CIRCULATIONAHA.111.029017
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet alfa for the reversal of factor Xa inhibitor activity. N. Engl. J. Med., 2015, 373, 2413-2424. DOI: https://doi.org/10.1056/NEJMoa1510991
Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest, 2005, 127, 1515-1522. DOI: https://doi.org/10.1378/chest.127.5.1515
Locke C, Ravnan SL, Patel R, Uchizono JA. Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy, 2005, 25, 685-689. DOI: https://doi.org/10.1592/phco.25.5.685.63582
Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE, Garcia DA. Delivery of optimized anticoagulant therapy: consensus statement from the anticoagulation forum. Ann. Pharmacother. 2013, 47, 714-724. DOI: https://doi.org/10.1345/aph.1R634
Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch. Intern. Med., 1998, 158. 1641-1647. DOI: https://doi.org/10.1001/archinte.158.15.1641
Bishop L, Young S, Twells L, Dillon C, Hawboldt J. Patients’ and physicians’ satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic. BMC Research Notes, 2015, 8, 233. DOI: https://doi.org/10.1186/s13104-015-1187-8
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
